News

ThromboGenics has revealed the results of phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema. The company said that the trial was designed

BioChemics has signed a research collaboration agreement with Unilever to utilize its proprietary topical delivery technology for the delivery of Unilever’s compounds. John Masiz, president and chief executive

Australia-based Cancer Therapeutics CRC (CTx) has collaborated with Duke University, North Carolina, USA (Duke) for the discovery and development of new drugs to treat many forms of cancer,

Seattle-based biotechnology company Theraclone Sciences has entered into a multi-year research and development agreement with Zenyaku Kogyo, a pharmaceutical company based in Tokyo. The collaboration will use Theraclone’s

GlaxoSmithKline (GSK) has received FDA’s Oncologic Drugs Advisory Committee (ODAC) recommendation in support of the approval of Votrient (pazopanib). Reportedly, the panel voted that the benefit-to-risk profile is

Cellix has entered into a distribution agreement with Germany-based Chromaphor Analysen-Tecknik, to handle sales and service agreements for Cellix products in Germany. Vivienne Williams, chief executive officer of

Cytopia and YM BioSciences (YM) have entered into an agreement in which YM will acquire all the issued shares and options in Cytopia. Shareholders are expected to vote

Inovio Biomedical (Inovio) has reported interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7

GlaxoSmithKline and XenoPort have reported top-line results from a phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN)